 |
|
|
| |
TURQUOISE-III: 12-Week Ribavirin-Free Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir for Patients With HCV Genotype 1b and Cirrhosis
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 san Francisco
Fred Poordad1, Jordan J Feld2, Roger Trinh3, Yves Horsmans4, Magdy Elkhashab5, Stefan Bourgeois6, Samuel S Lee7, Christophe Moreno8, David E Bernstein9, Ziad Younes10, Akshanth R Polepally3,
Kevin Howieson3, Bo Fu3, Nancy S Shulman3, Edward Tam11
1The Texas Liver Insti tute/University of Texas Health Science Center, San Antonio, Texas, United States; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States; 4Université Catholique de Louvain, Brussels, Belgium; 5Toronto Liver Centre, Toronto, Ontario, Canada; 6ZNA Stuivenberg, Antwerpen, Belgium; 7University of Calgary, Calgary, Alberta, Canada; 8CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 9North Shore University Hospital, Manhasset, New York, United States; 10GastroOne, Germantown, Tennessee, United States; 11LAIR Centre, Vancouver, British Columbia, Canada
|
| |
|
|
|
|
|
